A phase 1/2 trial of vaccination with autologous DCs pulsed with recombinant NS3 and core proteins combined with hIL-12 as an adjuvant has been completed for the treatment of patients with CHC (NCT03119025), and results are expected soon (Table 3). Here, KRAS is linked to cryohydrocytosis.